Literature DB >> 30373886

The 5-HT2A Receptor (5-HT2AR) Regulates Impulsive Action and Cocaine Cue Reactivity in Male Sprague-Dawley Rats.

Dennis J Sholler1, Sonja J Stutz1, Robert G Fox1, Edward L Boone1, Qin Wang1, Kenner C Rice1, F Gerard Moeller1, Noelle C Anastasio1, Kathryn A Cunningham2.   

Abstract

Impulsivity and the attentional orienting response to cocaine-associated cues (cue reactivity) promote relapse in cocaine-use disorder (CUD). A time-dependent escalation of cue reactivity (incubation) occurs during extended, forced abstinence from cocaine self-administration in rats. The investigational serotonin (5-HT) 5-HT2A receptor (5-HT2AR) antagonist/inverse agonist M100907 suppresses impulsive action, or the inability to withhold premature responses, and cocaine-seeking behaviors. The present preclinical study was designed to establish the potential for repurposing the Food and Drug Administration-approved selective 5-HT2AR antagonist/inverse agonist pimavanserin as a therapeutic agent to forestall relapse vulnerability in CUD. In male Sprague-Dawley rats, pimavanserin suppressed impulsive action (premature responses) measured in the 1-choice serial reaction time (1-CSRT) task, similarly to M100907. We also used the 1-CSRT task to establish baseline levels of impulsive action before cocaine self-administration and evaluation of cue reactivity (lever presses reinforced by the discrete cue complex previously paired with cocaine delivery). We observed an incubation of cocaine cue reactivity between day 1 and day 30 of forced abstinence from cocaine self-administration. Baseline levels of impulsive action predicted incubated levels of cocaine cue reactivity in late abstinence. We also found that baseline impulsive action predicted the effectiveness of pimavanserin to suppress incubated cue reactivity in late abstinence from cocaine self-administration at doses that were ineffective in early abstinence. These data suggest that integration of clinical measures of impulsive action may inform refined, personalized pharmacotherapeutic intervention for the treatment of relapse vulnerability in CUD. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30373886      PMCID: PMC6290084          DOI: 10.1124/jpet.118.251199

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  74 in total

1.  Impulsive behaviour in rats induced by intracortical DOI infusions is antagonized by co-administration of an mGlu2/3 receptor agonist.

Authors:  Lena Wischhof; Karl J Hollensteiner; Michael Koch
Journal:  Behav Pharmacol       Date:  2011-12       Impact factor: 2.293

2.  Individual Differences in Impulsive Action Reflect Variation in the Cortical Serotonin 5-HT2A Receptor System.

Authors:  Latham H L Fink; Noelle C Anastasio; Robert G Fox; Kenner C Rice; F Gerard Moeller; Kathryn A Cunningham
Journal:  Neuropsychopharmacology       Date:  2015-02-10       Impact factor: 7.853

3.  Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving.

Authors:  L C Maas; S E Lukas; M J Kaufman; R D Weiss; S L Daniels; V W Rogers; T J Kukes; P F Renshaw
Journal:  Am J Psychiatry       Date:  1998-01       Impact factor: 18.112

4.  Incubation of cocaine cue reactivity associates with neuroadaptations in the cortical serotonin (5-HT) 5-HT2C receptor (5-HT2CR) system.

Authors:  S E Swinford-Jackson; N C Anastasio; R G Fox; S J Stutz; K A Cunningham
Journal:  Neuroscience       Date:  2016-02-27       Impact factor: 3.590

5.  Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues.

Authors:  Kathryn A Cunningham; Robert G Fox; Noelle C Anastasio; Marcy J Bubar; Sonja J Stutz; F Gerard Moeller; Scott R Gilbertson; Sharon Rosenzweig-Lipson
Journal:  Neuropharmacology       Date:  2011-05-11       Impact factor: 5.250

Review 6.  Psychiatric aspects of impulsivity.

Authors:  F G Moeller; E S Barratt; D M Dougherty; J M Schmitz; A C Swann
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

7.  Impulsivity (delay discounting) as a predictor of acquisition of IV cocaine self-administration in female rats.

Authors:  Jennifer L Perry; Erin B Larson; Jonathan P German; Gregory J Madden; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

8.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

Review 9.  Neurocircuitry of addiction.

Authors:  George F Koob; Nora D Volkow
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

10.  Functional status of the serotonin 5-HT2C receptor (5-HT2CR) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence.

Authors:  Noelle C Anastasio; Sonja J Stutz; Robert G Fox; Robert M Sears; Ronald B Emeson; Ralph J DiLeone; Richard T O'Neil; Latham H Fink; Dingge Li; Thomas A Green; F Gerard Moeller; Kathryn A Cunningham
Journal:  Neuropsychopharmacology       Date:  2013-08-13       Impact factor: 7.853

View more
  9 in total

1.  Profile of cortical N-methyl-D-aspartate receptor subunit expression associates with inherent motor impulsivity in rats.

Authors:  Brionna D Davis-Reyes; Veronica M Campbell; Michelle A Land; Holly L Chapman; Susan J Stafford; Noelle C Anastasio
Journal:  Biochem Pharmacol       Date:  2019-07-08       Impact factor: 5.858

2.  Interactions between impulsivity and MDPV self-administration in rats.

Authors:  Megan S Abbott; Robert W Seaman; Michelle R Doyle; David R Maguire; Kenner C Rice; Gregory T Collins
Journal:  Addict Biol       Date:  2022-05       Impact factor: 4.093

3.  Role of neuropeptide neuromedin U in the nucleus accumbens shell in cocaine self-administration in male rats.

Authors:  Kathryn A Cunningham; Jonathan D Hommel; James M Kasper; Ashley E Smith; Sierra N Miller; William K Russell
Journal:  Neuropsychopharmacology       Date:  2021-12-16       Impact factor: 8.294

4.  Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial.

Authors:  Robert Suchting; Charles E Green; Constanza de Dios; Jessica Vincent; F Gerard Moeller; Scott D Lane; Joy M Schmitz
Journal:  Drug Alcohol Depend       Date:  2021-09-23       Impact factor: 4.492

5.  Subanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats.

Authors:  Brionna D Davis-Reyes; Ashley E Smith; Jimin Xu; Kathryn A Cunningham; Jia Zhou; Noelle C Anastasio
Journal:  Behav Pharmacol       Date:  2021-06-01       Impact factor: 2.277

6.  A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine.

Authors:  Liangsuo Ma; Kathryn A Cunningham; Noelle C Anastasio; James M Bjork; Brian A Taylor; Albert J Arias; Brien P Riley; Andrew D Snyder; F Gerard Moeller
Journal:  Transl Psychiatry       Date:  2022-05-06       Impact factor: 7.989

Review 7.  Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits.

Authors:  Manoranjan S D'Souza
Journal:  Front Psychiatry       Date:  2019-07-24       Impact factor: 4.157

8.  Blockade of 5-Hydroxytryptamine 2A Receptor Attenuates Precipitation of Naloxone-Induced Withdrawal Symptoms in Opioid-Exposed Mice.

Authors:  Bing Li; Junyu Jiang; Li Zhou; Xinrong Tao; Qixian Sun; Jiaxin Liu; Yang Liu; Gang Pang
Journal:  Front Behav Neurosci       Date:  2022-02-09       Impact factor: 3.558

9.  Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.

Authors:  Noelle C Anastasio; Dennis J Sholler; Robert G Fox; Sonja J Stutz; Christina R Merritt; James M Bjork; F Gerard Moeller; Kathryn A Cunningham
Journal:  Neuropharmacology       Date:  2020-02-14       Impact factor: 5.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.